

EACR

European Association
for Cancer Research

CONFERENCES

www.eacr.org

EACR Conference

Goodbye Flat Biology

ex vivo to in vivo models of cancer

23-25 September 2025 | Essen, Germany

Scientific Programme Committee

Valerie Weaver (Chair)
Emmanuel Donnadieu
Henriëtte Lanz

David Bryant
Viola Vogel

Scan the QR code to access online conference
resources, including speaker and poster abstracts

eacr.org/conference/goodbyeplatbiology2025



**Please be patient, the website may load slowly*



Hannah Barrs
Conference Officer



Kathryn Wass
Programmes Manager



Claire Sanders
Corporate Engagement
Manager

Conference dinner

Optional ticketed event (sold out) Wednesday 24 September, 19:30


The conference dinner will take place on the Wednesday night at the Kiepenkerl restaurant. It will be an excellent opportunity for participants and speakers to get to know each other in a relaxed and informal environment.

It is important that you bring your participant badge with you for entry to the dinner.

KIEPENKERL, Teichstraße 1, 45127 Essen | www.kiepenkerl-zu-essen.de

Getting to the restaurant from Messe Essen:

- Walk 2 minutes to the Underground U11 Gelsenkirchen Buerer Str.
- Travel 6 minutes (4 stops) to Essen Central Station
- Walk about 3 minutes to Restaurant Kiepenkerl



EACR Conference

CANCER NEURO- SCIENCE

14 - 16 October 2025, Bilbao

eacr.org/conferences

16 top speakers including:

Doug Hanahan
Leanne Li
Claire Magnon

Erica Sloan
Frank Winkler
Sebastien Talbot

Bringing together global leaders in this exciting and rapidly evolving field

Identifying the most relevant current insights, and developing a roadmap for future preclinical, translational and clinical research.

- Neural influences on cancer cells
- Neural influences on the tumor environment
- Influences of cancer (therapies) on the nervous system
- Cancer-intrinsic neural mechanisms

13 top speakers including:

Alberto Bardelli
Andrew Biankin
Yin Cao

Selma Masri
Shuji Ogino
Jelle Wesseling

Shaping the future of early-onset cancer research

Providing a unique platform to discuss the latest discoveries, promoting interdisciplinary collaboration, and identifying strategies for early detection, prevention, and treatment

- Systems and translational cancer epidemiology
- Molecular pathological epidemiology
- Precision-based cancer prevention/control strategies
- Molecular features of early-onset cancers
- Biological basis for cancer disparity

EACR-Mark Foundation for Cancer Research Joint Conference

THE RISE OF EARLY-ONSET CANCERS

Biology, Causes and Detection

11 - 13 November 2025, Bergamo

eacr.org/conferences

8 top speakers:

Cassandra Burdzyak Eduard Batlle
Frederic de Sauvage Mark Dawson
Raphael Rodriguez Ilaria Malanchi
Direna Alonso-Curbelo Adrienne A. Boire

Counteracting the adaptive prowess of cancer cells

Explore the fundamental mechanisms that control cancer cell plasticity at multiple biological levels, including the epigenome, transcriptome, metabolome, and cellular microenvironment

- Metastasis
- Therapy resistance
- Tumour heterogeneity
- Non-genetic adaptations in cancer cells
- Tumour-microenvironment interactions
- Therapy resistance

EACR Conference **CANCER CELL PLASTICITY:**

Cracking the Code of
Adaptation and Survival

Virtual event | 02 - 03 December 2025

eacr.org/conferences

EACR Conference **THE TUMOUR ECOSYSTEM**

From Mechanisms to
Novel Therapeutics

17 - 19 March 2026, Bergamo

eacr.org/conferences

15 top speakers including:

Johanna Joyce Yardena Samuels
Anna Obenauf Jacco van Rheenen
Erik Sahai Ashani Weeraratna
Ilaria Malanchi Andrea Schietinger

Explore cutting-edge
research and its
implications for novel
cancer therapies

- The role of inflammation and immunity in tumour progression and metastasis.
- Tumour-host interactions in response to therapy.
- Cancer interactions with the nervous system.
- Organ-specific metastatic niches.

Goodbye Flat Biology: ex vivo to in vivo models of cancer

Tag us   @helloeacr | Wi-Fi: EACR Password: GFB2026!

Day 1 | Tuesday 23 September

Session 1
posters can be
put up

From 11:30

REGISTRATION

12:00-13:00

WELCOME REFRESHMENTS

A chance to meet fellow attendees and enjoy a light buffet

13:00-13:10

CONFERENCE WELCOME

Scientific Programme Committee

13:10-13:35

Q&A: 13:35-13:50

SESSION 1: CELL-BASED THERAPIES

Chair: Valerie Weaver

OPENING KEYNOTE LECTURE

Michael Milone University of Pennsylvania, USA

'Navigating Beyond the Cancer Therapy Horizon with Engineered T cells'

13:50-14:10

Q&A: 14:10-14:20

Emmanuel Donnadieu Institut Cochin, France

'Predicting the Safety and Efficacy of Engineered T Cells Using an Ex Vivo Human Model'

14:20-14:30

Q&A: 14:30-14:35

Joash Joy Barts Cancer Institute, UK

Proffered Paper 1: 'Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity'

14:35-14:55

EXHIBITOR INTRODUCTIONS

14:45-15:25

COFFEE, EXHIBITION AND SOLO MEET-UP

Solo travellers are invited to meet up at the EACR banner to connect with fellow adventurers

15:25-15:45

Q&A: 15:45-15:55

Peter Friedl Radboud UMC, Netherlands

'Life or death: monitoring the first days of metastatic organ colonization'

15:55-16:15

Q&A: 16:15-16:25

Matt Paszek Cornell University, USA

'The sweet forces in control of 3D cellular morphology and function'

16:25-16:35

POSTER SPOTLIGHTS

Posters 1, 2 and 3 will be presented in 3-minute 'flash talks'

16:35-16:45
Q&A: 16:45-17:05

INVIVO BIOTECH SERVICES SYMPOSIUM

Tim Welsink InVivo BioTech Services

'Discover novel opportunities in antibody discovery, cell line development and functional single-cell analysis with Beacon® optofluidic technology'

17:05-17:35

NETWORKING QUIZ

17:35-18:25

WELCOME BUFFET AND DRINKS

18:25-19:55

POSTER DISCUSSION SESSION 1

Presenters of posters 1-68 should stand by their boards.

Day 2 | Wednesday 24 September

08:15-08:45

EARLY POSTER VIEWING WITH COFFEE

08:45-09:00

TECAN INDUSTRY SPOTLIGHT

Roman Petrovsky Tecan

'Label-free spheroids and organoids analysis for assays development'

09:00-09:20

Q&A: 09:20-09:30

SESSION 2: MECHANOBIOLOGY

Chair: Emmanuel Donnadieu

THE EMBO KEYNOTE LECTURE

Johanna Ivaska University of Turku, Finland

'3D matrix guided cues in cancer progression'

09:30-09:40

Q&A: 09:40-09:45

Maria Benito Jardon The Francis Crick Institute, UK
Proffered Paper 2: 'Melanoma cells orchestrate the composition of the tumour stroma via MRT-SRF signaling'

09:45-10:05

Q&A: 10:05-10:15

Sara Wickstrom Max Planck Institute, Germany
'Phenotype and cell state dynamics in cancer'

10:15-10:35

Q&A: 10:35-10:45

Thomas H. Barker University of Virginia, USA
'Mechanochemical dynamics of the provisional matrix critically instruct cell behaviors'

10:45-11:15

COFFEE BREAK & EXHIBITION

11:15-11:35

Q&A: 11:35-11:45

Samantha Stehbens

University of Queensland, Australia

'The Mechanobiology of Melanoma: Understanding How Tumour Cells Survive Metastasis'

Take down
session 1
posters

Session 2
posters can be
put up

11:45-11:55 Q&A: 11:55-12:00	Michelle Baird National Institutes of Health - NHLBI, USA Proffered Paper 3: 'Lamin B Receptor Upregulation in Melanoma Causes Cholesterol-Mediated Nuclear Envelope Fragility During Metastasis'
12:00-12:10	POSTER SPOTLIGHTS <i>Posters 69, 70 and 71 will be presented in 3-minute 'flash talks'</i>
12:10-12:30 Q&A: 12:30-12:40	PROMOCELL SYMPOSIUM Janina Moros PromoCell 'Goodbye Clumps, Hello Tumorspheres!'
12:40-13:40	 LUNCH BREAK <i>light refreshments will be served</i>
13:40-15:10	POSTER DISCUSSION SESSION 2 <i>Presenters of posters 69-134 should stand by their boards.</i>
15:10-15:30 Q&A: 15:30-15:40	SESSION 3: PLASTICITY Chair: Henriëtte Lanz G V Shivashankar ETH Zurich, Switzerland 'Mechano-genomics of tumor microenvironment and early diagnostics'
15:40-15:50 Q&A: 15:50-15:55	Anna Mukha Radboud UMC, Netherlands Proffered Paper 4: 'Mechanical challenges define the efficiency of the early organ colonization by tumor cells'
15:55-16:05 Q&A: 16:05-16:10	Bethany Bareham King's College London, UK Proffered Paper 5: 'Extracellular biomechanics and Immune Modulation in Oral Squamous Cell Carcinoma Cells'
16:10-16:30 Q&A: 16:30-16:40	Kevin Myant University of Edinburgh, UK 'Loss of colonic lineage fidelity permits induction of squamous-like plasticity and metastasis in colorectal cancer'
16:40-17:10	 COFFEE BREAK & EXHIBITION
17:10-17:30 Q&A: 17:30-17:40	Viola Vogel ETH Zurich, Switzerland 'Mechanoregulation of the reciprocal ECM-cell crosstalk: does the tension of individual ECM fibers matter?'
17:40-18:00 Q&A: 18:00-18:10	Chris Tape UCL Cancer Institute, UK 'Single-cell Phenoscaping of Tumour Microenvironment Organoids'
19:30	OPTIONAL CONFERENCE DINNER [SOLD OUT]  <i>The conference dinner will be held at Kiepenkerl in central Essen (separate ticketed event).</i>

Day 3 | Thursday 25 September

08:15-08:45



EARLY POSTER VIEWING WITH COFFEE

08:45-09:00

GREINER BIO-ONE SPOTLIGHT

Jennifer Bischoff Greiner Bio-One

'Magnetic 3D Cell Culture – A innovative tool to simplify 3D Cell Culture'

09:00-09:20

Q&A: 09:20-09:30

SESSION 4: MODELLING THE TUMOUR MICROENVIRONMENT

Chair: Viola Vogel

Henriëtte Lanz MIMETAS, Netherlands

'Influencing drug responses through in vitro tumour microenvironment characteristics'

09:30-09:50

Q&A: 09:50-10:00

Valerie Weaver UCSF, USA

'Leveraging 3D spheroids to clarify links between ECM stiffness and inflammation-dependent DNA damage and protumor mutations'

10:00-10:10

Q&A: 10:10-10:15

Oihane Mitxelena-Iribarren Biogipuzkoa HRI, Spain

Proffered Paper 6: '3D bone organotypic models of dormant breast cancer metastasis to study cell-extracellular matrix interactions as a strategy for new therapies'

10:15-10:45



COFFEE BREAK & EXHIBITION

10:45-11:05

Q&A: 11:05-11:15

David Bryant CRUK Beatson Institute, UK

'Examining the contribution of PTEN to colorectal cancer using in vitro-to-in vivo transplantation and CRISPR-mediated knockout.'

11:15-11:40

Q&A: 11:40-11:55

CLOSING KEYNOTE LECTURE

Frances Balkwill CRUK City of London Centre, UK

'3D multicellular models of ovarian cancer'

11:55

SUMMARY, AWARDS AND DEPART

GET
UPDATES:
eacr.org/congress

Annual Congress of the

EACR 2026

08 - 11 June | Budapest

Innovative Cancer Science

European Association for Cancer Research

**OUTSTANDING
SCIENCE IN A
WELCOMING
ENVIRONMENT**

**GREAT NETWORKING
OPPORTUNITIES
WITH 2000+ CANCER
RESEARCHERS**

**98% OF
PARTICIPANTS
WOULD
RECOMMEND**

SESSION TOPICS INCLUDE:

- Advances in Clinical Trial Design
- Cancer and RNA modifications
- Cancer Immunology and Immunotherapy
- Cancer Initiation
- Cancer Prevention
- Cell Cycle Regulation

- Cell Death Mechanisms
- Functional Genomics
- Genomic Instability
- Immune Activation beyond T cells
- Mechanisms of Tumour Metastasis
- Novel Cancer Models
- Plasticity and Non-genetic

- Cancer Evolution
- Spatial Tumour Biology / Tumour Heterogeneity at the Single Cell Level
- Tumors are Ecosystems: New insights on the Tumor Microenvironment
- Tumour Innervation
- Tumour Macroenvironment (cachexia, metabolics)

Travel grants

More information about EACR grants: eacr.org/travel-grant

EACR-Worldwide Cancer Research Travel Grants provide funds to help early-career EACR members and researchers based in low- or middle-income economy countries to participate in our conferences.

Congratulations to the recipients of the Travel Grants for this conference. Each recipient received a full registration free of charge and funds to assist with travel and accommodation costs.

- **MAITANE DUARTE GARCIA-ESCUADERO**, SPAIN
- **JAKUB GUBALA**, SWITZERLAND
- **MARIA-DANAE JESSEL**, UK
- **MARAHAINI MUSA**, MALAYSIA
- **LALEH RAFIEE**, TURKEY
- **SABRINA STECHER**, GERMANY
- **YIZHENG ZHANG**, GERMANY

worldwide
cancer
research

EACR
European Association
for Cancer Research

Supporters

Our thanks to the following partners for supporting us in promoting this conference:




We would also like to thank the following grant providers:



This activity has been supported by a grant from F. Hoffman-La Roche Ltd, which has had no control over the educational content of this activity.

Venue floor plan



Exhibitors

- | | |
|--------------------------------|----------------------------|
| 1. Sarstedt | 8. InVivo BioTech Services |
| 2. ABclonal | 9. VectorBuilder |
| 3. MedChemExpress | 10. React4Life |
| 4. PromoCell | 11. ibidi |
| 5. Instech Laboratories Europe | 12. Gelomics |
| 6. Greiner Bio-One | 13. Tecan |
| 7. Cellsense Technologies | 14. LGC |
| | 15. Kugelmeiers |

Meet the exhibitors

Sarstedt Stand: 1

Website: www.sarstedt.com

Represented at the conference by:
Sarhink Mella



ABclonal Stand: 2

Website: www.abclonal.com

Represented at the conference by:
Sara Albarran, Jing Lu



MedChemExpress Stand: 3

Website: www.medchemexpress.com

Represented at the conference by:
Mahdi Rivandi, Jidnyasa Gujar



PromoCell Stand: 4

Website: www.instechlabs.com

Represented at the conference by:
Janina Moros, Aileen Mischke, Alexander Trampe



Symposium: Wednesday 24 September | 12:10-12:40

Janina Moros 'Goodbye Clumps, Hello Tumorspheres!'

Instech Laboratories Europe Stand: 5

Website: www.instechlabs.com

Represented at the conference by:
Thomas Penning



Greiner Bio-One Stand: 6

Website: www.gbo.com

Represented at the conference by:
Jennifer Bischoff, Myrjam Frischauf



Spotlight: Thursday 25 September | 08:45-09:00

Jennifer Bischoff 'Magnetic 3D Cell Culture - A innovative tool to simplify 3D Cell Culture'

Cellsense Technologies Stand: 7

Website: www.cellsense-technologies.com

Represented at the conference by:
Vitaliy Oliynyk, Gerd Behme



InVivo BioTech Services Stand: 8

Website: www.invivo.de

Represented at the conference by:

Olaf Degen, Haijie Li, Tim Welsink



Symposium: Tuesday 23 September | 16:20-16:50

Tim Welsink 'Discover novel opportunities in antibody discovery, cell line development and functional single-cell analysis with Beacon® optofluidic technology'

VectorBuilder Stand: 9

Website: www.vectorbuilder.com

Represented at the conference by: Dominik Aschauer



React4Life Stand: 10

Website: www.react4life.com

Represented at the conference by:

Maurizio Aiello, Silvia Scaglione



ibidi Stand: 11

Website: www.ibidi.com

Represented at the conference by:

Christiane Thanisch, Judith Stolwijk



Gelomics Stand: 12

Website: www.gelomics.com

Represented at the conference by:

Christoph Meinert



Tecan Stand: 13

Website: www.tecan.com

Represented at the conference by:

Tobias Mortsiefer, Roman Petrovsky



Spotlight: Wednesday 24 September | 08:45-09:00

Roman Petrovsky 'Label-free spheroids and organoids analysis for assays development'

LGC Stand: 14

Website: www.lgcstandards-atcc.org

Represented at the conference by:

Rebecca Conrad, Michael Wißing



Kugelmeiers Stand: 15

Website: www.kugelmeiers.com

Represented at the conference by: Manfred Vogel



Proffered paper and poster index

View abstracts when logged in at www.eacr.org/conference/goodbyeflatbiology2025

Poster Spotlight session 1: Tuesday, 16:25 | Also as posters on Tuesday

1 A Perfusable Microvascularised Tumour-on-Chip Model Emulating Endothelial Glycocalyx Remodeling and Nanoparticle Dynamics in Human Hepatocellular Carcinoma **Presented by Emre Doganay, University College London, UK**

2 Modelling bone marrow adipocyte-mediated therapy resistance in advanced prostate cancer: insights from humanized bone models and metabolic treatment co-targeting **Presented by Nathalie Bock, Queensland University of Technology & Max Planck Queensland Centre, Brisbane, AUSTRALIA**

3 Aging shapes tissue dynamics, drug response and cellular dissemination of spheroid cultures **Presented by Olivier De Wever, Ghent University, BELGIUM**

Poster Spotlight session 2: Wednesday, 12:00 | Also as posters on Wednesday

69 Development of the in vitro 3D Spheroid High-Throughput Screening Platform for the Evaluation of Immune Checkpoint Inhibitors **Presented by Irina Agarkova, Insphero AG, Schlieren, SWITZERLAND**

70 Disrupting RAS–PI3K signaling in CAFs reprograms the extracellular matrix and unveils microenvironmental vulnerabilities in KRAS-driven lung cancer **Presented by Cristina Cuesta, CSIC–Universidad de Salamanca, SPAIN**

71 Shaping the environment: how HGSOc cells orchestrate the immune microenvironment in a 3D human model **Presented by Beatrice Malacrida, Queen Mary University of London, UK**

Poster presentations session 1: Tuesday, 18:25 - 19:55

4 Modelling the Mechanisms of Pancreatic Cancer Metastasis Using a 3D Microfluidic System **Presented by Melati Suhaila Abdul Halim, Leibniz Institute of Polymer Research Dresden, GERMANY**

5 Impact of CAFs on the intratumoral distribution and anticancer activity of albumin-targeting drug **Presented by Barbora Adamová, Medical University of Vienna, AUSTRIA**

6 An innovative immune-on-chip platform for studying tumor-immune interactions and evaluating novel immunomodulatory therapies **Presented by Maurizio Aiello, React4life S.p.A. & National Research Council of Italy, Genoa, ITALY**

7 *Abstract withdrawn*

8 Colorectal cancer patient-derived organoids to study the impact of Wnt/-catenin signalling on CAR-T cell cytotoxicity in vitro **Presented by Emmanouil Angelidakis, Institut Pasteur, Paris & École Polytechnique, Palaiseau, FRANCE**

9 Linking tumor glycosylation to HER2-targeting therapies: insights from 3D models and clinical data **Presented by Uxue Armendáriz-Martínez, CIC bioGUNE, Derio, SPAIN**

10 Uncovering targetable roles of the extracellular matrix in cancer using precision biomaterials **Presented by Jennifer Ashworth, University of Nottingham, UK**

11 BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer with wild-type KRAS **Presented by Stella Asmanidou, University of Stuttgart, GERMANY**

12 Investigating ADI-PEG20/gemcitabine treatment in epithelioid pleural mesothelioma: from in vitro studies to novel in ovo xenograft models **Presented by Sarah Barnett, University of Liverpool, UK**

- 13 Dual Inhibition of GOT1 and HMGR Exhibits Enhanced Antiproliferative Effect on Cancer Cells Presented by Elif Bayram, Bursa Uludag University, TURKEY
- 14 Patient-Derived lymphoma Spheroids as preclinical models for predicting patient responses to advanced therapies in B-NHL: example of glofitamab in follicular lymphoma Presented by Christine Bezombes, Université de Toulouse, FRANCE
- 15 Modeling Esophageal Squamous Cell Carcinoma in Microfluidic 3D Systems to Investigate CDK4/6 Inhibition and Tumor-Immune Interactions Presented by Xavier Bisteau, Université Libre de Bruxelles, BELGIUM
- 16 Understanding the contribution of CAF phenotypes and ECM heterogeneity in the development of prostate cancer Presented by Matthew Blakeley, Imperial College London, UK
- 17 Modelling Hyperglycaemia within the Colorectal Cancer Tumour Microenvironment Presented by Charlotte Boyd, Sheffield Hallam University, UK
- 18 Using human 3D in vitro models to understand the evolution of serous tubal intraepithelial carcinoma lesions to high grade serous ovarian cancer Presented by Rachel Bryan-Ravenscroft, Queen Mary University of London, UK
- 19 Impact of Stromal-Tumor Interactions on Drug Response in Pancreatic Cancer: Co-culture of CAFs With Patient-Derived Organoids Presented by Verona Buocikova, Slovak Academy of Sciences, Bratislava, SLOVAK REPUBLIC
- 20 Every Component Matters: Extracellular Matrix and its value in testing immunotherapeutics Presented by Eugenia Cambiaso, UMC Utrecht, NETHERLANDS
- 21 An ex vivo platform to predict chemotherapy response in non-small cell lung cancer patients Presented by Zhongli Chen, Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS
- 22 The Role of Multinucleated Giant Cells in Circulating Tumor Microemboli During Pancreatic Ductal Adenocarcinoma Metastasis Presented by Hung-Jen Chien, Academia Sinica, Taipei, TAIWAN ROC
- 23 Harnessing PPP2R1A-Mediated Phosphoproteome and Autophagy Rewiring to Identify Novel Therapeutic Strategies in Uterine Serous Carcinoma Presented by Valentina Clausi, IRCCS & University of Rome "Tor Vergata", Rome, ITALY
- 24 Development and Molecular Profiling of Drug-resistant Tumoroid Models from Colon Cancer Patients Presented by Alexandre Coelho, Universidade do Porto, PORTUGAL
- 25 Application of nucleoside analog labeling to study the cell cycle of xenografted PDAC cell lines in the chorioallantoic membrane model Presented by Robin Colenbier, University of Antwerp, BELGIUM
- 26 From flat to functional: advancing endometrial cancer models through 3D bioprinting Presented by Emma Coschina, University of Bologna, ITALY
- 27 Eosinophils exert protective effects in bladder cancer development Presented by Marina Degoricija, University of Split, CROATIA
- 28 Tau silencing via siRNA-loaded lipid nanoparticles enhances chemosensitivity in ovarian cancer 3D models Presented by Roberta Di Fonte, IRCCS Istituto Tumori Giovanni Paolo II, Bari, ITALY
- 29 TKI sensitivity of ROS1+ lung cancer cell lines in 2D versus 3D culturing conditions Presented by Christa Dijkhuizen, Hanze University of Applied Sciences, Groningen, NETHERLANDS
- 30 Targeting PCSK9 reduces stem-like features and chemoresistance in metastatic colorectal cancer cells Presented by Maitane Duarte Garcia-Escudero, University of the Basque Country (UPV/EHU), Leioa, SPAIN

- 31 From shape to function: dissecting the role of morphology as a driver of glioblastoma stem cell behavior Presented by Stefania Faletti, Human Technopole, Milan, ITALY
- 32 Lung-mimicking click alginate-dECM model of breast cancer lung metastasis reveals the role of ECM stiffness in cancer growth dynamics Presented by Laura Fallert, Biogipuzkoa & CICbiomaGUNE, Donosti-San Sebastian, SPAIN
- 33 Three-dimensional in vitro models characterization, development, and evaluation in preclinical ADC development Presented by Jiaxin Fan, Imperial College London, UK
- 34 BACE2-Dependent Collagen Regulation Modulates Extracellular Matrix Anisotropy, Promoting Cancer Cell Migration and Drug Resistance Presented by Francesco Farris, IFOM ETS - The AIRC Institute of Molecular Oncology, Milano, ITALY
- 35 E-cadherin dysfunction activates a nucleus-dependent invasive program in gastric cancer Presented by Joana Figueiredo, University of Porto, PORTUGAL
- 36 Gene Expression Profiling of MCF7 Cells Grown in 3D Liquid Versus 3D Matrigel: Insights into Stemness Regulation Presented by Rong Fu, University of Bristol, UK
- 37 Ex vivo patient-derived tumour slices as a tool for cancer drug discovery Presented by Fabien Garcon, AstraZeneca, Cambridge, UK
- 38 Patient-Derived Tumour Organoids as translational models for pulmonary neuroendocrine carcinomas Presented by Lucia Giordanengo, University of Turin, Orbassano, ITALY
- 39 On-a-Chip Innovation: Bridging Vessels and Tumors for Smarter Chemotherapy Decisions Presented by Karina Goluba, University of Latvia, Riga, LATVIA
- 40 Overcoming Therapeutic Resistance: Remodelling the Prostate Cancer Microenvironment using Liposomal Nanomedicines Presented by Kyle Greenland, Imperial College London, UK
- 41 Integrating Hypoxia and CAFs into 3D Spheroid Models Unmasks Synergistic Drug Resistance in Renal Cancer Presented by Jakub Gubala, University of Geneva, SWITZERLAND
- 42 Metabolism-oriented compound screen in physiological culture conditions identifies growth conditions and compounds highly effective against drug-naïve and -resistant melanoma cells Presented by Claude Haan, University of Luxembourg, Belvaux, LUXEMBOURG
- 43 Mapping drug responses in humanized 3D models of the ovarian cancer ecosystem: dissecting the role of cancer-associated fibroblasts with multiplexed single-cell transcriptomics Presented by Maria Hincapié-Otero, University of Helsinki, FINLAND
- 44 Immune-checkpoint blockade drives patient-derived tissue cultures (PDTs) of gastric cancer into hypoxia and tumor evasion Presented by Ngoc Anh Hoang, Health and Medical University Potsdam & Leipzig University Medical Center, GERMANY
- 45 Mesenteries as an advanced ex vivo co-culture platform to study mechanisms of peritoneal metastasis Presented by Kerstin Huebner, Friedrich Alexander University ErlangenNürnberg, GERMANY
- 46 Developing a biomimetic 3D model for obesity-associated endometrial cancer research. Presented by Tiffany Ilott, University of Otago Christchurch, NEW ZEALAND
- 47 Human Precision-Cut Tumour Slices (hPCTS) and Immune Co-Culture Systems to Assess and Enhance Immunotherapy Response in Cholangiocarcinoma Presented by Maria-Danae Jessel, University of Liverpool, UK
- 48 Identification of novel potential substrates of the E3-ubiquitin ligase Hakai and its impact on Wnt/-catenin pathway Presented by Lia Jove, Universidade da Coruña, SPAIN

49 From Cell Lines to Organotypic Slice Cultures: A 3D Platform for Testing Epigenetic and Immune-Based Therapies in Pancreatic Ductal Adenocarcinoma Presented by Lucia Juhasikova, Slovak Academy of Sciences, Bratislava, SLOVAK REPUBLIC

50 Advancing Colorectal Cancer Research Through 3D Microenvironmental Models of Tumor Invasion and Drug Screening Presented by Tamara Juriňáková, Masaryk University, Brno, CZECH REPUBLIC

51 Engineered 3D bone-mimetic niches for studying niche-induced metastatic breast cancer dormancy Presented by Evrim Ceren Kabak, University of Basel, SWITZERLAND

52 Selective Tumor Treg Depletion by EGL-001, a CTLA4-CD25 Antagonist Fusion Antibody Presented by Anupama Karnam, Egle Therapeutics, Suresnes, FRANCE

53 Automation of long term dynamic drug testing for clinical implementation of real world precision oncology Presented by Jens Michael Kelm, PreComb Therapeutics AG, Hombrechtikon, SWITZERLAND

54 Genetic deletion of ULK1 suppresses tumor progression in a Kras-driven lung cancer mouse model Presented by Jihyeon Kim, National Cancer Center, Gyeonggi-do, SOUTH KOREA

55 Bioengineering breast cancer PDO models using tuneable gelatin-based ECM mimicking hydrogels Presented by Anu Thomas Koikaletu, Queensland University of Technology & Max Planck Queensland Centre, Brisbane, AUSTRALIA

56 Immune Surveillance in 3D: Microfluidic Models Reveal Dynamic Crosstalk Between Natural Killer Cells and Glioblastoma Presented by Tina Kolenc Milavec, National Institute of Biology & Jožef Stefan International Postgraduate School, Ljubljana, SLOVENIA

57 Continuous cromolyn exposure enhances bladder cancer progression Presented by Jelena Korac-Prlc, University of Split, CROATIA

58 Complex patient-derived tissue cultures reveal differences in cell death mechanisms in lung cancer subtypes Presented by Angelique Kragl, Health and Medical University Potsdam, GERMANY

59 High-throughput generation of 3D mammary tumor models using an optimized microinjection-based platform Presented by Ana Krotenberg Garcia, CIC bioGUNE, Derio, SPAIN

60 Impact of Physical Constraints on Glioblastoma Cell Plasticity using Tumoroid Cultured in Acoustic Levitation Presented by Shuake Kuermanbayi, Sorbonne Université & CNRS UMR7636, Paris, FRANCE

61 Loss of the tumor suppressor DLC1 promotes cell invasion through multicellular streaming in 3D models of breast cancer Presented by Fiona Kühnel, University of Stuttgart, GERMANY

62 Bioreactor-based culture of ovarian carcinomas preserves tumor microenvironment and allows testing of standard and novel therapeutics Presented by Ivana Kurelac, University of Bologna & IRCCS, Bologna, ITALY

63 From Flat to Functional: A Comparative Study of 2D, Spheroids, and 3D Advanced Bioprinted Models for Investigating Drug Resistance in Cutaneous Squamous Cell Carcinoma (cSCC) Presented by Agata Kurzyk, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, POLAND

64 TopBP1 Overexpression Drives Malignant Transformation in 3D Breast Epithelial Spheroids Presented by Mayurika Lahiri, Indian Institute of Science Education and Research, Pune, INDIA

65 Ex Vivo Tumour-Immune Co-Culture For Functional Checkpoint Inhibitor Screening Presented by Louis Lane, The University of Sheffield, UK

66 Exploiting patient-derived organoids to test immunotherapy approaches against glioblastoma Presented by Gloria Leva, University of Trento, ITALY

67 Targeting B4GALT3 to Suppress Tumor Progression and Reprogram the Immune Microenvironment in Hepatocellular Carcinoma Presented by Ying-Yu Liao, National Taiwan University, Taipei City, TAIWAN ROC

68 3D Culture Reveals Distinct Morphological and Transcriptional Changes in Carboplatin-Resistant Ovarian Cancer Cells Presented by Lucija Librenjak, Ruđer Bošković Institute, Zagreb, CROATIA

Poster presentations session 2: Wednesday, 13:40-15:10

72 3D Patient-Derived Primary Tumor Microtissues: Next Level In Vitro Model for Scalable and Reliable Preclinical Drug Testing Presented by Laure-Anne Ligeon, Insphero, Schlieren, SWITZERLAND

73 Mapping patient specific prostate cancer stroma interactions in a three-dimensional bioengineered tumour microenvironment Presented by Johannes Low Jun Wei, Dresden University of Technology, GERMANY

74 Human mammary 3D spheroid models uncover the role of filopodia in breaching the basement membrane to facilitate invasion Presented by Frédéric Luton, Université Côte d'Azur, Sophia-Antipolis, FRANCE

75 Investigating the effects of cannabidiol in a physiologically relevant model of prostate cancer Presented by Rianna Magee, University College Dublin, IRELAND

76 Cells decrease their volumes and cell cycle progression rates during formation of multicellular structures Presented by Vaibhav Mahajan, Center for Molecular and Cell Biology, Dresden, GERMANY

77 Development of an advanced in vitro model of malignant mesothelioma using animal-free hydrogels Presented by Zain Mahmood, University of Strathclyde, Glasgow, Scotland, UK

78 Modelling Tumour–Stroma Interactions in Desmoplastic Small Round Cell Tumours Using a Novel 3D Patient-Derived Co-Culture System Presented by Stella Man, Institute of Cancer Research, Sutton, UK

79 Cathepsin B-Driven Regulation of Fibroblast Dynamics and Matrix Reorganization in the Breast Cancer Microenvironment Presented by Erik Maquoi, University of Liège, BELGIUM

80 Understanding the Abscopal effect in Prostate cancer – Primary and Metastatic Tumour Crosstalk Presented by Nuria Mascaro Fortuno, Imperial College London, UK

81 Modeling breast cancer microenvironment on-chip to study tumor resistance Presented by Claudia Mazio, Istituto Italiano di Tecnologia, Napoli, ITALY

82 Degradome-wide screening identified calpain-2 as a pro-invasive factor in prostate cancer Presented by Ruusu-Maaria Merivirta, University of Helsinki, FINLAND

83 Untangling the role of collagen fibre networks in complex breast cancer cell interactions Presented by Samantha Mitchell, University of Nottingham, UK

84 Targeting Tenascin-C to enforce radiotherapy-induced tumor remission Presented by Ioanna Mitrentsi, INSERM U1109, Strasbourg, FRANCE

86 Early-stage patient-derived NSCLC organoids are predictive of chemo adjuvant and target therapy efficacy Presented by Valentina Monica, University of Torino, Orbassano, ITALY

87 Development of a microfluidic platform for 3D lung tumor culture to study immune cell migration and tertiary lymphoid structure organization in the tumor microenvironment Presented by Ana Ximena Monroy-Romero, Sorbonne University, Paris, FRANCE

88 Goodbye clumps, hello uniform tumorspheres Presented by Janina Moros, PromoCell GmbH, Heidelberg, Baden-Württemberg, GERMANY

- 89 Harnessing 3D Air-Liquid Interface Models to Uncover Soluble and EV-Associated Biomarkers for Non-Small Cell Lung Cancer Diagnosis Presented by Sive Mullen, Trinity College Dublin & Maynooth University, IRELAND
- 90 RBPMS as a Cancer-Associated Fibroblast Marker in Differentiating the Mechanisms of Right- and Left-Sided Colorectal Cancer Presented by Marahaini Musa, Universiti Sains Malaysia, Kubang Kerian, MALAYSIA
- 91 Engineering cell fate in cancer organoids using synthetic 3D matrix cues Presented by Ali Nadernezhad, Leibniz Institute of Polymer Research Dresden, GERMANY
- 92 An Optimized AGE-Supplemented Murine Model Increased RAGE Expression and Primed Prostate for Tumorigenesis Presented by Michael Nelappana, University of Illinois & Beckman Institute, Champaign, Illinois, USA
- 93 Cancer cell/fibroblast heterospheroids as models for combination therapy: combining chemotherapeutic agents and immune cells Presented by Boye S Nielsen, Bioneer, Horsholm, DENMARK
- 94 Patient derived organoids to investigate inter and intra-patient heterogeneity in ovarian high grade serous carcinoma Presented by Katherine Nixon, Imperial College London, UK
- 95 Effects of Thermal Inkjet Bioprinting on Spheroid Formation in MDA MB231 and MDA MB468 Cells: Advancing Triple-Negative Breast Cancer (TNBC) Models for Personalized Medicine Presented by Renata Ortega, The University of Texas, El Paso, USA
- 96 Engineering biomimetic patient-derived lung tumor organoid models Presented by Ece Ozturk, Koç University, Istanbul, TURKEY
- 97 Translational Genomics in Uveal Melanoma and Renal Cell Carcinoma Presented by Samuel Peña-Llopis, University Hospital Essen, GERMANY
- 98 Modelling the breast tumour microenvironment: Enabling direct interaction between breast cancer cells and mature adipocytes Presented by Elisabeth Phillips, University of Otago Christchurch, NEW ZEALAND
- 99 The role of the glutamylase TTLL6 in colon homeostasis and pathology Presented by Vanessa Pires, Université de Montpellier, FRANCE
- 100 Colorectal cancer and Bacteroides fragilis 3D co-culture model Presented by Matěj Prikryl, Masaryk University, Brno, CZECH REPUBLIC
- 101 Advancing 3D Cell Culture: Microfluidic Chip Facilitates Spheroid Handling and Bio-Imaging Presented by Laleh Rafiee, Istanbul Medipol University, TURKEY & Isfahan University of Medical Sciences, IRAN
- 102 The FACT complex as a critical regulator of growth and immune response in oral squamous cell carcinoma Presented by Graziella Ribeiro de Sousa, University of São Paulo, BRAZIL & Linköping University, SWEDEN
- 103 Neutrophil-derived chitinase 3-like 1 drives immunosuppression in triple-negative breast cancer: insights from a CHI3L1 knockout mouse model Presented by Robbe Salembier, Ghent University & Cancer Research Institute Ghent, BELGIUM
- 104 Laccase-Catalyzed Green Synthesis of Collagen 3D Scaffolds for Tumor Modeling Presented by Giulia Sbanchi, IRCCS, Meldola, ITALY
- 105 Recreating Fasting-Driven Therapeutic Responses in a Dynamic Human 3D Tumor Model Presented by Silvia Scaglione, React4life & CNR, Genoa, ITALY
- 106 Inflammatory and Metabolic Profiling of Gastrointestinal Cancers Using Fresh Human Ex Vivo Explants Presented by Nick Schellenberg, Trinity College Dublin, IRELAND
- 107 Integrating Spatial Metabolomics by MALDI Imaging into Studying Organotypic Slice Cultures of Human Bladder Cancer Presented by Rabea Schwarz, University of Freiburg, GERMANY

108 Intestinal stem cell marker MEX3A acts as a PPAR direct regulator with functional impact in colorectal carcinogenesis Presented by Ana Rita Silva, Universidade do Porto & Porto Comprehensive Cancer Center, PORTUGAL

109 Advancing Preclinical Models for Leiomyosarcoma: Comparative Analysis of 3D models Presented by Antonella Simone, University of Bologna, ITALY

110 In vitro spheroid-based Non-Small Cell Lung Cancer angiogenic pre-clinical model for advancing the development of effective cancer therapeutics Presented by Tecla Simone, Trinity College Dublin, IRELAND

111 Microfluidic fabrication of siRNA-loaded lipid nanoparticles targeting MAPT in 3D ovarian cancer models Presented by Federica Sommonte, IRCCS Istituto Tumori Giovanni Paolo II, Bari, ITALY

112 3D Bioprinted Breast Cancer Model with Real-Time Tracking to Dissect Stromal Cell-Guided Cancer Cell Migration and Invasion Presented by Sabrina Stecher, University Hospital Wuerzburg, GERMANY

113 Beyond apoptosis: XIAP orchestrates melanoma vascular mimicry Presented by Joy Steinkamp, University of Cologne, GERMANY

114 Testing viability of cellular models of giant cell-rich lesions of bone on matrixes with potential use in bioprinting Presented by Běla Stejskalová, MUNI, Brno, CZECH REPUBLIC

115 Analysis of uterine gland elongation regulated by EGF and ECM composition in 3D culture systems Presented by Yosuke Sugino, Okayama University, JAPAN

116 Impact of Hypoxia on Uveal Melanoma Cell Growth and Radioresistance in a 3D In Vitro Model Presented by Piotr Świerzewski, Jagiellonian University, Kraków, POLAND

117 The influence of neutrophil granulocytes on the treatment response to EGFR-TKIs in lung cancer Presented by Yousef Tallouzi, University of Southern Denmark, Odense, DENMARK

118 Mouse colon organotypic tissue slices as a model for peritoneal metastasis Presented by Daniela Thalheim, Friedrich-Alexander Universität Erlangen-Nürnberg, GERMANY

119 Etoposide-induced protein 2.4 homolog confers cancer resistance to DNA-damaging agents by promoting homologous recombination repair Presented by Le Tran Nhat, Yonsei University Wonju College of Medicine, SOUTH KOREA

120 Extracellular Matrix-Driven Network-Based Patient Stratification Reveals Distinct Molecular Grades with Potential Clinical Implications Presented by Nurcan Tuncbag, Koc University, Istanbul, TURKEY

121 Advanced 3D Liver Models as in vitro alternatives for the pre-clinical assessment of mRNA-LNP- based Cancer Immunotherapies Presented by Melissa Anne Tutty, Trinity College Dublin, IRELAND

122 Cryopreserved 3D Human Tumor Spheroid Platform in 96-well Format for Robust & Scalable Drug Discovery and Screening Presented by Baerbel Ulmer, InSphero, Zürich, SWITZERLAND

123 Development of 3D Multicompartment In Vitro Models to Investigate Bone Metastasis in Breast Cancer Presented by Anuja Upadhyay, University College London, UK

124 Modeling the tumor stroma of pancreatic cancer for preclinical testing combination therapies Presented by Maria Urbanova, Slovak Academy of Sciences, Bratislava, SLOVAK REPUBLIC

125 Proteomic Insights into the Extracellular Matrix of Metastatic Ovarian High Grade Serous Carcinoma: Paving the Way for Improved Organoid Model Culture Systems Presented by Shriya Varghese, Imperial College London, UK

- 126 Modulation of PARP expression by hypoxia in irradiated colorectal cancer cells
Presented by Kristijonas Velickevicius, National Cancer Institute & Vilnius University, Vilnius, LITHUANIA
- 127 Modeling NER syndromes in 3D cell cultures to understand skin tumorigenesis
Presented by Gaia Veniali, CNR-Istituto di Genetica Molecolare, Pavia, ITALY
- 128 Targeting EGLN1 to Overcome Drug Resistance in KRAS-Mutant Lung Adenocarcinoma: A Patient-Derived Organoid Study Presented by Giulio Verna, Azienda USL-IRCCS di Reggio Emilia, ITALY
- 129 Modelling pancreatic ductal adenocarcinoma mechanics with PXDO-on-chip technology Presented by Isabel Villaoslada, Hospital Universitario Miguel Servet, Zaragoza, SPAIN
- 130 Uncovering GLI2 Transcriptional Targets in 3D Cancer Spheroid Models Presented by Nikolina Vučemilo Paripović, Institute Ruder Bošković, Zagreb, CROATIA
- 131 Modeling drug response in renal cell carcinoma cell lines: impact of 3D-tumor spheroid architecture on cabozantinib efficacy and c-MET signaling Presented by Angela Zaccagnino, Saarland University, Homburg, Saarland, GERMANY
- 132 A multi-omics analysis of effector and resting Treg cells in pan-cancer Presented by Apostolos Zaravinos, European University Cyprus & Basic and Translational Cancer Research Center, Nicosia, CYPRUS
- 133 Development of a Personalized Intestinal Organoid Model to Study IBD and Intestinal Fibrosis Presented by Eliska Zgarbova, St. Anne's University Hospital in Brno, CZECH REPUBLIC & Cedars-Sinai Medical Center, Los Angeles, USA
- 134 An Ex Vivo 3D Bioreactor Model of Human Cancer Tissue for Immunotherapies Testing Presented by Yizheng Zhang, University Hospital and Comprehensive Cancer Center Tübingen, GERMANY

Notes

Notes

Notes

Communication.
Collaboration.
Community.

EACR

European Association
for Cancer Research



**NOT A MEMBER
YET? JOIN NOW**

Apply for funding
to develop your
research &
expand
your
horizons



Benefit from
reduced
registration
rates at EACR
events

Join our online
networking
events



Build new
connections
with our 'Find a
Collaborator'
tool

Search
the EACR
Member
Network
and message
other members



Share your
perspective: write
for The Cancer
Researcher
magazine

Access
our free
expert
webinars on
research &
careers



Stay informed
with regular
updates on
news, jobs, and
conferences

Volunteer for
our Ambassador
Programme or
committees

EACR Industry Partners

The European Association for Cancer Research gratefully acknowledges its Industry Partners, who offer ongoing support to the EACR and provide the means for the association to develop important initiatives.

